We enrolled patients aged 12–70 years with Alport syndrome diagnosed histologically (by electron microscopy) or genetically by a documented mutation in disease-associated genes, including COL4A3, COL4A4, or COL4A5. Genetic testing was conducted as part of the trial by an independent vendor (Machaon Diagnostics, Oakland, CA, USA) unless patients provided documentation of prior genetic or histological diagnosis for eligibility. Patients had eGFR between 30 and 90 mL/min/1.73 m2 (inclusive) and urinary albumin to creatinine ratio (UACR) ≤3,500 mg/g. Patients with macroalbuminuria (UACR of 301–3,500 mg/g) were to comprise no >40% of enrolled trial participants. Patients were to have received maximally tolerated labeled doses of an angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB), unless medically contraindicated. Patients with clinically significant cardiovascular disease or serum B-type natriuretic peptide concentrations >200 pg/mL during screening were not eligible for the study. Patients with uncontrolled diabetes and/or hypertension were also excluded.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.